Results 51 to 60 of about 16,038 (249)

Convalescent plasma therapy in COVID-19 and discharge status

Journal of Family Medicine and Primary Care, 2021
Objective: Covid19 has emerged as a greatest threat of the decade worldwide. At present there is no certain treatment for treating coronavirus diseases, while some antiviral drugs (Remdesivir , Lopinavir and Ritonavir) are under investigation.
Neeraj Agarwal, Shradha Mishra, Arshad Ayub   +2 more
openaire   +3 more sources

Therapeutic Apheresis in Nigeria: A Multi‐Center Summary of Abstracts From the Inaugural Nigerian Society for Apheresis Scientific Meeting

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Therapeutic apheresis (TA) is an established treatment modality for hematologic, neurologic, and immunologic disorders, yet access remains severely limited in sub‐Saharan Africa. Donor apheresis, including platelet apheresis collection from healthy donors, represents an important complementary modality supporting blood product ...
Nosa Bazuaye, Chimezie Okwuonu, Evelyn Idam, Folasade Adelekan‐Popoola, Shakirat Gold‐Olufadi, Olufunto Olufela Kalejaiye, Abdullateef Ogala, Zinnah Aloziem, Blossom Amamchukwu, Patience Elimia, Mkpoikanabasi Obot‐Obot, Henry Mbakwe, Praises Maduagwuna, Olatunji Akinrodoye, Chiamaka Anyanwu, Benjamin Anyanwu, Adedamola Akinsiku, Oluwatoyin A. Akinsiku, Muzamil O. Hassan, Fatiu A. Arogundade, Olalekan E. Ojo, Homayemem Weli, Jesupelumi Adenihun, Aderemi Adelaja, Ebun Bamgboye, Olalekan Olatise, Ade E. Faponle, Ayoola Odeyemi, Michael Muoka, Stephen Asaolu, Qudrat Busari, Blessing Dawudu, Michael Naiyeju, Rasheed A. Balogun   +33 more
wiley   +1 more source

Convalescent plasma therapy in severe coronavirus disease-2019: A narrative review

Indian Journal of Rheumatology, 2020
Passive immunotherapy using whole blood or plasma from recovered patients is a potential therapeutic strategy for infections with no known drug therapy or prophylactic vaccines.
Rasmi Ranjan Sahoo, Kasturi Hazarika, Prashant Bafna, Manesh Manoj, Anupam Wakhlu   +4 more
doaj   +1 more source

Establishing an Apheresis Medicine Program in a Resource‐Constrained Setting: A 5‐Year Experience From Lagos, Nigeria

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Establishing a comprehensive apheresis medicine program in a resource‐constrained setting presents significant structural, financial, and logistical challenges. Despite the growing clinical importance of apheresis services globally, published experience from sub‐Saharan Africa remains sparse.
Folasade Adelekan‐Popoola, Shakirat Gold‐Olufadi, Olufunto Olufela Kalejaiye, Abdullateef Ogala, Rasheed A. Balogun   +4 more
wiley   +1 more source

Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)

Scientific Reports, 2022
There is a need for effective therapy for COVID-19 pneumonia. Convalescent plasma has antiviral activity and early observational studies suggested benefit in reducing COVID-19 severity.
Karin van den Berg, Tanya Nadia Glatt, Marion Vermeulen, Francesca Little, Ronel Swanevelder, Claire Barrett, Richard Court, Marise Bremer, Cynthia Nyoni, Avril Swarts, Cordelia Mmenu, Thomas Crede, Gerdien Kritzinger, Jonathan Naude, Patryk Szymanski, James Cowley, Thandeka Moyo-Gwete, Penny L. Moore, John Black, Jaimendra Singh, Jinal N. Bhiman, Prinita Baijnath, Priyesh Mody, Jacques Malherbe, Samantha Potgieter, Cloete van Vuuren, Shaun Maasdorp, Robert J. Wilkinson, Vernon J. Louw, Sean Wasserman   +29 more
doaj   +1 more source

Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19

Viruses, 2021
The use of convalescent plasma in the treatment of COVID-19 may lead to a milder course of infection and has been associated with improved outcomes.
Monika Maria Biernat, Anna Kolasińska, Jacek Kwiatkowski, Donata Urbaniak-Kujda, Paweł Biernat, Justyna Janocha-Litwin, Małgorzata Szymczyk-Nużka, Dawid Bursy, Elżbieta Kalicińska, Krzysztof Simon, Grzegorz Mazur, Tomasz Wróbel   +11 more
doaj   +1 more source

Degradation mechanism of the von Willebrand factor A2 domain by nattokinase

FEBS Letters, EarlyView.
Nattokinase, a natto‐derived protease, exhibits potent antithrombotic effects. This study demonstrates that nattokinase directly cleaves the von Willebrand factor (vWF) A2 domain in vitro. Unlike the native regulator ADAMTS13, nattokinase degrades folded vWF independently of shear stress.
Ryuichi Hyakumoto, Masatomo So, Ayako Furukawa, Kenji Sugase   +3 more
wiley   +1 more source

Perplexing Issues for Convalescent Immune Plasma Therapy in COVID-19

Northern Clinics of Istanbul, 2021
Convalescent immune plasma (CIP) therapy in coronavirus disease 2019 (COVID-19) is presently a trendy choice of treatment. On March 24, 2020, the United States Food and Drug Administration approved of CIP treatment for seriously ill COVID-19 patients as an emergency investigational new drug. The precise mechanisms of action for CIP in COVID-19 have not
openaire   +3 more sources

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source

Plasma convalescent therapy for COVID-19 patients: A literature review.

Revista de la Facultad de Medicina Humana, 2020
Introduction: The coronavirus disease 2019 (COVID-19) caused by the new coronavirus infection (SARS-CoV-2) has created a pandemic that has led to a global fight to cope with the large number of infected people, many of which require intensive care.
Tania Platero-Portillo, Sussan Llocclla-Delgado, Nehemias Guevara-Rodriguez   +2 more
doaj   +1 more source